MedPath

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Phase 2
Completed
Conditions
Dementia Alzheimer's Type
Interventions
Drug: placebo (for SAR110894)
Registration Number
NCT01266525
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

- To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on stable donepezil therapy

Secondary Objectives:

* To explore the effect of SAR110894 on functional impairment, global clinical status and behavioral disturbances;

* To assess the safety/tolerability of SAR110894;

* To assess pharmacokinetic (PK) of SAR110894 and concentrations of donepezil;

* To explore caregiver time consumption and distress changes.

Detailed Description

The total study duration for each patient is approximatively 36 - 38 weeks broken down as follows:

* Screening period: up to 4 weeks,

* Treatment period: 24 weeks,

* Follow-up period: 10 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
291
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SAR110894 - 0.5 mgSAR110894SAR110894, 0.5 mg once daily along with Donepezil.
SAR110894 - 2 mgSAR110894SAR110894, 2 mg once daily along with Donepezil.
Placeboplacebo (for SAR110894)Placebo (for SAR110894) once daily along with Donepezil.
SAR110894 - 5 mgSAR110894SAR110894, 5 mg once daily along with Donepezil.
SAR110894 - 0.5 mgDonepezilSAR110894, 0.5 mg once daily along with Donepezil.
SAR110894 - 2 mgDonepezilSAR110894, 2 mg once daily along with Donepezil.
SAR110894 - 5 mgDonepezilSAR110894, 5 mg once daily along with Donepezil.
PlaceboDonepezilPlacebo (for SAR110894) once daily along with Donepezil.
Primary Outcome Measures
NameTimeMethod
Change from baseline to Week 24 in the standard 11-item total score from the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog).Week 4, 12, and 24
Secondary Outcome Measures
NameTimeMethod
Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) global scoreWeek 4, 12, and 24
Change from baseline in each of the two remaining items of the ADAS-Cog (namely "delayed word recall" and "concentration/distractibility")Week 4, 12, and 24
Change from baseline in each of the five factors from the Cognitive Drug Research System (CDR-S) computerized assessmentWeek 4, 12, and 24
Change from baseline in the Mini Mental State Examination (MMSE) total scoreWeek 4, 12, and 24

Trial Locations

Locations (82)

Investigational Site Number 840024

🇺🇸

Costa Mesa, California, United States

Investigational Site Number 840041

🇺🇸

Gilbert, Arizona, United States

Investigational Site Number 616004

🇵🇱

Bydgoszcz, Poland

Investigational Site Number 840034

🇺🇸

Darien, Connecticut, United States

Investigational Site Number 840009

🇺🇸

Hattiesburg, Mississippi, United States

Investigational Site Number 616001

🇵🇱

Gdynia, Poland

Investigational Site Number 616005

🇵🇱

Warszawa, Poland

Investigational Site Number 840014

🇺🇸

Franklin, Tennessee, United States

Investigational Site Number 840021

🇺🇸

Bennington, Vermont, United States

Investigational Site Number 616006

🇵🇱

Szczecin, Poland

Investigational Site Number 620002

🇵🇹

Amadora, Portugal

Investigational Site Number 620001

🇵🇹

Lisboa, Portugal

Investigational Site Number 840001

🇺🇸

Redlands, California, United States

Investigational Site Number 840005

🇺🇸

W Palm Beach, Florida, United States

Investigational Site Number 840026

🇺🇸

Sherman Oaks, California, United States

Investigational Site Number 840002

🇺🇸

Santa Ana, California, United States

Investigational Site Number 840030

🇺🇸

La Jolla, California, United States

Investigational Site Number 840015

🇺🇸

Hialeah, Florida, United States

Investigational Site Number 036005

🇦🇺

Waratah, Australia

Investigational Site Number 036001

🇦🇺

Nedlands, Australia

Investigational Site Number 840003

🇺🇸

Delray Beach, Florida, United States

Investigational Site Number 840025

🇺🇸

Quincy, Massachusetts, United States

Investigational Site Number 840031

🇺🇸

Williamsburg, Virginia, United States

Investigational Site Number 036008

🇦🇺

Heidelberg West, Australia

Investigational Site Number 380002

🇮🇹

Milano, Italy

Investigational Site Number 380001

🇮🇹

Milano, Italy

Investigational Site Number 840004

🇺🇸

Jacksonville, Florida, United States

Investigational Site Number 840039

🇺🇸

Charlotte, North Carolina, United States

Investigational Site Number 250006

🇫🇷

Paris, France

Investigational Site Number 036003

🇦🇺

Woodville, Australia

Investigational Site Number 036006

🇦🇺

Herston, Australia

Investigational Site Number 276009

🇩🇪

Würzburg, Germany

Investigational Site Number 380006

🇮🇹

Ancona, Italy

Investigational Site Number 250009

🇫🇷

Limoges, France

Investigational Site Number 124004

🇨🇦

Toronto, Canada

Investigational Site Number 840040

🇺🇸

Eatontown, New Jersey, United States

Investigational Site Number 840018

🇺🇸

Cedarhurst, New York, United States

Investigational Site Number 036009

🇦🇺

Toowoomba, Australia

Investigational Site Number 124008

🇨🇦

Ottawa, Canada

Investigational Site Number 036007

🇦🇺

Chermside, Australia

Investigational Site Number 124014

🇨🇦

Halifax, Canada

Investigational Site Number 616003

🇵🇱

Gdansk, Poland

Investigational Site Number 380003

🇮🇹

Milano, Italy

Investigational Site Number 250004

🇫🇷

Bordeaux, France

Investigational Site Number 250007

🇫🇷

Marseille, France

Investigational Site Number 250008

🇫🇷

Strasbourg Cedex, France

Investigational Site Number 124013

🇨🇦

Regina, Canada

Investigational Site Number 124001

🇨🇦

London, Canada

Investigational Site Number 124002

🇨🇦

Toronto, Canada

Investigational Site Number 036004

🇦🇺

Randwick, Australia

Investigational Site Number 276008

🇩🇪

München, Germany

Investigational Site Number 124010

🇨🇦

Calgary, Canada

Investigational Site Number 380005

🇮🇹

Cefalù, Italy

Investigational Site Number 250005

🇫🇷

Nice, France

Investigational Site Number 724008

🇪🇸

Madrid, Spain

Investigational Site Number 124003

🇨🇦

Sherbrooke, Canada

Investigational Site Number 276012

🇩🇪

Dresden, Germany

Investigational Site Number 124006

🇨🇦

St. John, Canada

Investigational Site Number 276001

🇩🇪

Schwerin, Germany

Investigational Site Number 616002

🇵🇱

Poznan, Poland

Investigational Site Number 380004

🇮🇹

Castellanza, Italy

Investigational Site Number 250003

🇫🇷

Nantes, France

Investigational Site Number 250001

🇫🇷

Lille Cedex, France

Investigational Site Number 124015

🇨🇦

Gatineau, Canada

Investigational Site Number 724002

🇪🇸

Algorta, Spain

Investigational Site Number 724001

🇪🇸

Barcelona, Spain

Investigational Site Number 840032

🇺🇸

Phoenix, Arizona, United States

Investigational Site Number 840006

🇺🇸

Miami, Florida, United States

Investigational Site Number 840013

🇺🇸

Fresno, California, United States

Investigational Site Number 840008

🇺🇸

Baton Rouge, Louisiana, United States

Investigational Site Number 840037

🇺🇸

Tulsa, Oklahoma, United States

Investigational Site Number 036002

🇦🇺

Adelaide, Australia

Investigational Site Number 124009

🇨🇦

Greenfield Park, Canada

Investigational Site Number 124011

🇨🇦

Montreal, Canada

Investigational Site Number 276011

🇩🇪

Berlin, Germany

Investigational Site Number 276007

🇩🇪

München, Germany

Investigational Site Number 250002

🇫🇷

Toulouse Cedex 3, France

Investigational Site Number 724003

🇪🇸

Terrassa, Spain

Investigational Site Number 724007

🇪🇸

Sevilla, Spain

Investigational Site Number 840011

🇺🇸

Tampa, Florida, United States

Investigational Site Number 840038

🇺🇸

Austin, Texas, United States

Investigational Site Number 840012

🇺🇸

Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath